CUMBERLAND PHARMS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?
CUMBERLAND PHARMS has three approved drugs.
There are fifteen US patents protecting CUMBERLAND PHARMS drugs.
There are sixty-nine patent family members on CUMBERLAND PHARMS drugs in seventeen countries and one supplementary protection certificate in one country.
Summary for CUMBERLAND PHARMS
| International Patents: | 69 |
| US Patents: | 15 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for CUMBERLAND PHARMS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | ACETADOTE | acetylcysteine | INJECTABLE;INTRAVENOUS | 021539-001 | Jan 23, 2004 | AP | RX | Yes | Yes | 8,722,738 | ⤷ Subscribe | ⤷ Subscribe | |||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | 11,806,400 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Cumberland Pharms | LACTULOSE | lactulose | FOR SOLUTION;ORAL | 074712-002 | Dec 10, 1997 | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CUMBERLAND PHARMS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-001 | Jun 11, 2009 | 6,727,286 | ⤷ Subscribe |
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | 6,727,286 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
International Patents for CUMBERLAND PHARMS Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102625656 | ⤷ Subscribe |
| Japan | 2009506030 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2012012640 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CUMBERLAND PHARMS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1781277 | PA2024501 | Lithuania | ⤷ Subscribe | PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
